However, recent studies have identified acquired EZH2 mutations in lymphoma cancer [49], myeloid neoplasms [50] and melanoma that are associated with the development of malignancy by regulating the expression of the complex of PcG genes to determine cell fate [9, 19, 51]. Here, EZH2 is linked to myeloid neoplasm.